Background Acral melanoma is a rare melanoma subtype with poor prognosis. Importantly. these patients were not identified as a specific subgroup in the landmark melanoma trials involving ipilimumab and the anti-programmed cell death protein-1 (PD-1) agents nivolumab and pembrolizumab. There is therefore an absence of prospective clinical trial evidence regarding the efficacy of checkp... https://cosmeticssquadets.shop/product-category/brightening-moisturiser/